Hamostaseologie 2019; 39(04): 404-408
DOI: 10.1055/s-0039-1679929
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl

C. Schneider
1   Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
E. Stutz-Grunder
1   Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
S. Lüer
1   Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
P. Keller
2   Department of Hematology, University Hospital/Inselspital Bern and University of Bern, Bern, Switzerland
,
J. A. Kremer Hovinga
2   Department of Hematology, University Hospital/Inselspital Bern and University of Bern, Bern, Switzerland
,
R. A. Ammann
1   Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
A. Karow
1   Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

04. September 2018

17. Januar 2019

Publikationsdatum:
20. März 2019 (online)

Abstract

Background Essential thrombocythemia is a chronic myeloproliferative neoplasm. It is extremely rare in children below 15 years of age with an estimated annual incidence of only 0.09 per million. Usually, clinical symptoms associated with essential thrombocythemia are mild or absent.

Case Here, we present the case of a 14-year-old female patient fulminantly presenting with acute symptoms comprising visual impairment, palmar and plantar stabbing pain. Blood count revealed massive thrombocytosis of 2373 × 109/L. Bone marrow morphology showed elevated numbers of mature megakaryocytes. Von Willebrand factor activity/antigen ratio was significantly reduced compatible with an acquired Von Willebrand syndrome associated with high platelet counts. Molecular analyses for driver mutations of myeloproliferative neoplasms including JAK2V617F, CALR and MPL were negative. Acute therapy comprising hyperhydration and oxygen supply complemented by acetylsalicylic acid led to amelioration of symptoms. Medication with hydroxycarbamide maintained a significant reduction of platelet counts but had to be reduced or withheld several times due to neutropenia. Repeated bleeding episodes observed in the course were clearly associated with increases in platelet counts above 1200 × 109/L explained by acquired von Willebrand syndrome. Sixteen months after diagnosis, therapy was switched to pegylated interferon and platelet counts could be stabilized without significant side effects.

 
  • References

  • 1 Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000; 110 (03) 751
  • 2 Fu R, Zhang L, Yang R. Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br J Haematol 2013; 163 (03) 295-302
  • 3 Karow A, Nienhold R, Lundberg P. , et al. Mutational profile of childhood myeloproliferative neoplasms. Leukemia 2015; 29 (12) 2407-2409
  • 4 Birgegård G. Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol 2015; 6 (03) 142-156
  • 5 Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015; 1 (01) 97-105
  • 6 Subramaniam N, Mundkur S, Kini P, Bhaskaranand N, Aroor S. Clinicohematological study of thrombocytosis in children. ISRN Hematol 2014; 2014: 389257
  • 7 Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005; 129 (02) 165-177
  • 8 Wang JL, Huang LT, Wu KH, Lin HW, Ho MY, Liu HE. Associations of reactive thrombocytosis with clinical characteristics in pediatric diseases. Pediatr Neonatol 2011; 52 (05) 261-266
  • 9 Kirkineska L, Perifanis V, Vasiliadis T. Functional hyposplenism. Hippokratia 2014; 18 (01) 7-11
  • 10 Lundberg P, Karow A, Nienhold R. , et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123 (14) 2220-2228
  • 11 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82 (06) 1749-1757
  • 12 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
  • 13 van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994; 69 (02) 81-84
  • 14 Strouse JJ, Lanzkron S, Beach MC. , et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122 (06) 1332-1342
  • 15 Gisslinger H, Gotic M, Holowiecki J. , et al; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121 (10) 1720-1728